These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1133 related articles for article (PubMed ID: 7042068)

  • 1. Actinomycin-D plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamine (DTIC) with or without intravenous Corynebacterium parvum in metastatic malignant melanoma.
    Robidoux A; Gutterman JU; Bodey GP; Hersh EM
    Cancer; 1982 Jun; 49(11):2246-51. PubMed ID: 7042068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclophosphamide plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) with or without Corynebacterium parvum in metastatic malignant melanoma.
    Presant CA; Bartolucci AA; Smalley RV; Vogler WR
    Cancer; 1979 Sep; 44(3):899-905. PubMed ID: 383276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corynebacterium parvum followed by chemotherapy (actinomycin D and DTIC) compared with chemotherapy alone for metastatic malignant melanoma.
    Thatcher N; Wagstaff J; Mene A; Smith D; Orton C; Craig P
    Eur J Cancer Clin Oncol; 1986 Aug; 22(8):1009-14. PubMed ID: 3770045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DTIC and actinomycin D with and without C. parvum immunotherapy in advanced malignant melanoma.
    Halpern J; Catane R; Biran S; Fuks Z
    Tumori; 1981; 67(3):215-7. PubMed ID: 7281240
    [No Abstract]   [Full Text] [Related]  

  • 5. Ineffectiveness of adjuvant chemotherapy using DTIC and cyclophosphamide in patients with resectable metastatic melanoma.
    Balch CM; Murray D; Presant C; Bartolucci AA
    Surgery; 1984 Apr; 95(4):454-9. PubMed ID: 6369594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized study of Corynebacterium parvum adjuvant therapy following surgery for (stage II) malignant melanoma.
    Thatcher N; Mene A; Banerjee SS; Craig P; Gleave N; Orton C
    Br J Surg; 1986 Feb; 73(2):111-5. PubMed ID: 3512025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I--II study of intermittent bolus administration of DTIC and actinomycin D in metastatic malignant melanoma.
    Samson MK; Baker LH; Talley RW; Fraile RJ; McDonald B
    Cancer Treat Rep; 1978 Aug; 62(8):1223-5. PubMed ID: 356980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoimmunotherapy for disseminated malignant melanoma: a prospective randomized study.
    Ramseur WL; Richards F; Muss HB; Rhyne L; Cooper MR; White DR; Stuart JJ; Spurr CL
    Cancer Treat Rep; 1978 Jul; 62(7):1085-7. PubMed ID: 356970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A trial of imidazole carboxamide and corynebacterium parvum in disseminated melanoma: clinical and immunologic results.
    Clunie GJ; Gough IR; Dury M; Furnival CM; Bolton PM
    Cancer; 1980 Aug; 46(3):475-9. PubMed ID: 6994866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
    Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
    Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination chemotherapy using adriamycin, DTIC, cyclophosphamide, and actinomycin D for advanced soft tissue sarcomas: a randomized comparative trial. A phase III, Southwest Oncology Group Study (7613).
    Baker LH; Frank J; Fine G; Balcerzak SP; Stephens RL; Stuckey WJ; Rivkin S; Saiki J; Ward JH
    J Clin Oncol; 1987 Jun; 5(6):851-61. PubMed ID: 3295129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoimmunotherapy (DTIC and Corynebacterium parvum) as adjuvant treatment in malignant melanoma.
    Karakousis CP; Didolkar MS; Lopez R; Baffi R; Moore R; Holyoke ED
    Cancer Treat Rep; 1979; 63(11-12):1739-43. PubMed ID: 393377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled study with imidazole carboxamide (DTIC), DTIC + bacillus Calmette-Guérin (BCG), and DTIC + corynebacterium parvum in advanced malignant melanoma. W.H.O. Collaborating Centres for Evaluation of Methods of Diagnosis and Treatment of Melanoma.
    Tumori; 1984 Feb; 70(1):41-8. PubMed ID: 6369694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trials of chemotherapy and chemoimmunotherapy in primary malignant melanoma.
    Jacquillat C; Banzet P; Maral J
    Recent Results Cancer Res; 1982; 80():254-8. PubMed ID: 7036288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoimmunotherapy (DTIC and Corynebacterium parvum) for disseminated malignant melanoma.
    Karakousis CP; Didolkar MS; Han T
    Cancer Treat Rep; 1981; 65(9-10):925-6. PubMed ID: 7273032
    [No Abstract]   [Full Text] [Related]  

  • 17. A clinical trial of procarbazine plus vincristine plus bis-chloroethyl-nitrosourea plus imidazole carboxamide dimethyl triazeno in metastatic malignant melanoma.
    Van Dyk JJ; Falkson G
    Med Pediatr Oncol; 1975; 1(2):107-11. PubMed ID: 1228411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dibromodulcitol (DBD), DTIC, and actinomycin-D in disseminated malignant melanoma. A phase I-II clinical trial.
    Samson MK; Haas CD; Baker LH; Cummings G
    Am J Clin Oncol; 1985 Apr; 8(2):167-71. PubMed ID: 3834791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoimmunotherapy of disseminated malignant melanoma with DTIC-BCG, transfer factor + melphalan.
    Schwarz MA; Gutterman JU; Burgess MA; Heilbrun LK; Murphy WK; Bodey GP; Stone E; Turner-Chism V; Hersh EM
    Cancer; 1980 May; 45(10):2506-15. PubMed ID: 7378986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlled study of DTIC versus DTIC plus epirubicin in metastatic malignant melanoma.
    Lopez M; Perno CF; Di Lauro L; Papaldo P; Ganzina F; Barduagni A
    Invest New Drugs; 1984; 2(3):319-22. PubMed ID: 6392148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.